Abstract: 【Abstract】 Immune checkpoint inhibitors, represented by programmed death-1 （PD-1）/programmed death-ligand 1 （PD-L1） inhibitors, are a breakthrough in the treatment of malignant tumors, and the following immune-related adverse events cannot be ignored. Stevens-Johnson syndrome （SJS）/toxic epidermal necrolysis （TEN） is one of the most serious adverse events, which can be life-threatening. Compared with SJS/TEN caused by other drugs, SJS/TEN associated with PD-1/PD-L1 inhibitors tends to have a longer latent period, more extensive and more severe skin lesions, higher risk of complications such as severe infection and organ failure, poorer prognosis, and higher mortality. So, early diagnosis and correct treatment are of great significance. This review summarizes current research progress in SJS/TEN associated with PD-1/PD-L1 inhibitors.

Key words: Programmed cell death 1 receptor, Antigens, CD274, Stevens-Johnson syndrome, Drug toxicity, Autoimmunity, Biological agents